Common Blood Thinner Prasugrel Shows Surprising Promise Against Lupus

A new study published in Nature Communications has uncovered a groundbreaking use for the antiplatelet drug Prasugrel. Researchers found it could treat systemic lupus erythematosus (SLE) by targeting key immune pathways. The discovery suggests existing medications may hold untapped potential for autoimmune diseases.

The study reveals that Prasugrel works by acetylating cyclic GMP-AMP synthase (cGAS), a protein critical in the innate immune response. This modification prevents cGAS from binding to DNA, blocking the activation of the STING pathway. As a result, chronic inflammation—a hallmark of SLE—is significantly reduced.

Tests across in vitro models, genetically modified mice, and patient-derived immune cells consistently showed improvements. Prasugrel suppressed lupus-like symptoms and lowered levels of pro-inflammatory cytokines. Transcriptomic analysis further confirmed its ability to reprogram immune responses by dampening interferon-stimulated genes. Beyond SLE, the findings hint at broader applications. Prasugrel's mechanism could benefit other autoimmune and inflammatory diseases linked to TLR7 and cGAS-STING pathways. The research also underscores the role of post-translational modifications, like acetylation, in fine-tuning immune sensors. Despite these advances, no clinical trials are currently investigating Prasugrel for SLE. Public registries, including ClinicalTrials.gov and the EU Clinical Trials Register, list zero ongoing or completed studies as of March 2026. Further research remains essential to refine dosing and fully grasp its immunomodulatory effects.

The study positions Prasugrel as a promising candidate for repurposing in autoimmune treatment. Its ability to modulate immune pathways offers a new direction for precision medicine in SLE. However, clinical validation is still required before it can move from lab findings to patient care.